Patrick Henning to lead CLSA’s Federal, State and Local Government Relations, Communications, Policy and Alliance Development Efforts on behalf of California’s life sciences sector
House overwhelmingly passes year-end spending deal that includes a permanent repeal of the 2.3% medical device tax, Senate likely to approve
CLSA Disappointed by House Passage of H.R. 3, Legislation That Will Short-Circuit Treatments for Patients and California Innovation
On Dec. 12, the U.S. House is set to vote on H.R. 3, a bill that will have catastrophic consequences for patients and California’s life sciences sector. Learn why in this STAT News op-ed from CLSA CEO Mike Guerra.
On November 18, 2019, as a result of the advocacy of CLSA’s Washington, D.C. based team and the leadership of Congressman Lou Correa (D-Santa Ana), a California Democratic Delegation letter was sent to House Leadership urging swift action to repeal the medical device tax before the end of the year.
Looking ahead at 2020, we anticipate a ballot crowded with initiatives, many of which could have a significant impact on California’s life sciences industry. The issues being covered range from consumer privacy, which we have previously discussed at length, to commercial property taxes and funding for California’s stem cell agency.
CLSA recently released the findings of a CLSA-commissioned study, conducted by international health economics firm Vital Transformation, to examine the impact of using international reference pricing in Medicare Part D (as proposed in H.R. 3, the Lower Drug Costs Now Act of 2019) on California’s innovative biotechnology sector.
The enactment of the California Consumer Privacy Act of 2018 (AB 375) (CCPA) brought sweeping restrictions on the collection and use of consumer information. A clean-up bill that same year, SB 1121 (Dodd), added key exceptions to the CCPA to help protect clinical trials and other biomedical research from unintended consequences, including exceptions for, among other things, protected health information (PHI) under federal law and information collected as part of a clinical trial subject to various laws and guidelines.
California Life Sciences Association was recently featured in the San Diego Union-Tribune regarding its new study on the impact of international reference pricing. Up to 88 percent fewer new drug approvals projected in study commissioned by Biocom and California Life Sciences Association.
Life Sciences Trade Groups Warn Congress: International Reference Pricing Proposals Included in Bills like H.R. 3 Undermine Hope for Patients and America’s Leadership in Biomedical Innovation